insights_auto
Why is ABCL down 6.19%?
Dive Deeperchevron_right
ABCL:NASDAQ
AbCellera Biologics Inc
$12.27
arrow_downward
-6.19%(-0.81) 1D
$12.20
arrow_downward
-0.57% (-0.070)bedtimeAfter hours
Closed: Oct 30, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABCL...
Open
$12.65
High
$12.91
Low
$11.75
Mkt. cap
3.97B
Avg. vol.
4.79M
Volume
3.88M
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.54
Beta
1.41
Shares outstanding
324.05M
No. of employees
562
Open
$12.65
High
$12.91
Low
$11.75
Mkt. cap
3.97B
Avg. vol.
4.79M
Volume
3.88M
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.54
Beta
1.41
Shares outstanding
324.05M
No. of employees
562
News stories
From web sources and news partners
Investing.com
·
16 hours ago
Jefferies initiates AbCellera stock coverage with buy rating
Profile
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
About AbCellera Biologics Inc
CEOCarl Hansen
Employees562
Founded2012
HeadquartersVancouver, British Columbia, Canada
SectorHealth care
Websiteabcellera.com